Cargando…
Coronavirus disease 2019 and non-alcoholic fatty liver disease
The coronavirus disease 2019 (COVID-19) pandemic may present with a broad range of clinical manifestations, from no or mild symptoms to severe disease. Patients with specific pre-existing comorbidities, such as obesity and type 2 diabetes, are at high risk of coming out with a critical form of COVID...
Autores principales: | Bellanti, Francesco, Vendemiale, Gianluigi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8473503/ https://www.ncbi.nlm.nih.gov/pubmed/34630869 http://dx.doi.org/10.4254/wjh.v13.i9.969 |
Ejemplares similares
-
Hepatic Mitochondria-Gut Microbiota Interactions in Metabolism-Associated Fatty Liver Disease
por: Bellanti, Francesco, et al.
Publicado: (2023) -
Redox Homeostasis and Immune Alterations in Coronavirus Disease-19
por: Bellanti, Francesco, et al.
Publicado: (2022) -
Impact of sodium glucose cotransporter-2 inhibitors on liver steatosis/fibrosis/inflammation and redox balance in non-alcoholic fatty liver disease
por: Bellanti, Francesco, et al.
Publicado: (2022) -
Microbial metabolites in non-alcoholic fatty liver disease
por: Zhou, Da, et al.
Publicado: (2019) -
Nuclear factor erythroid 2-related factor 2-mediated signaling and metabolic associated fatty liver disease
por: Bukke, Vidyasagar Naik, et al.
Publicado: (2022)